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Abstract. Duchenne muscular dystrophy is a lethal genetic 
disease of childhood caused by primary abnormalities in the gene 
coding for the membrane cytoskeletal protein dystrophin. The 
mdx mouse is an established animal model of various aspects 
of X-linked muscular dystrophy and is widely used for studying 
fundamental mechanisms of dystrophinopathy and testing 
novel therapeutic approaches to treat one of the most frequent 
gender-specific diseases in humans. In order to determine global 
changes in the muscle proteome with the progressive deteriora-
tion of mdx tissue with age, we have characterized diaphragm 
muscle from mdx mice at three ages (8-weeks, 12-months and 
22-months) using mass spectrometry-based proteomics. Altered 
expression levels in diaphragm of 8-week vs. 22-month mice 
were shown to occur in 11 muscle-associated proteins. Aging in 
the mdx diaphragm seems to be associated with a drastic increase 
in the extracellular matrix proteins, collagen and dermatopontin, 
the molecular chaperone αB-crystallin, and the intermediate 
filament protein vimentin, suggesting increased accumula-
tion of connective tissue, an enhanced cellular stress response 
and compensatory stabilization of the weakened membrane 
cytoskeleton. These proteomic findings establish the aged mdx 
diaphragm as an excellent model system for studying secondary 
effects of dystrophin deficiency in skeletal muscle tissue.
Introduction
The largest human gene spans 2.5 Mb of the X-chromosome 
and encodes the membrane cytoskeletal protein dystrophin of 
427 kDa (1). Primary abnormalities in the dystrophin gene lead 
to a functional absence of the full-length Dp427 isoform and 
trigger Duchenne muscular dystrophy, a progressive neuromus-
cular disease of childhood (2). The muscular dystrophy X-linked 
(mdx) mouse is an established animal model of various aspects 
of X-linked muscular dystrophy and is widely used for studying 
fundamental mechanisms of dystrophinopathy and testing novel 
therapeutic approaches to treat one of the most frequent gender-
specific diseases in humans (3). A single base substitution within 
exon 23 of the dystrophin gene causes premature termination 
of the dystrophin polypeptide chain in mdx mice (4). Although 
most individual muscles in the mdx mouse do not represent a 
perfect replica of the fiber wasting pathology observed in the 
highly progressive etiology of Duchenne muscular dystrophy, 
certain muscle types show many molecular and cellular altera-
tions that are characteristic of dystrophinopathy.
The mdx mouse shows i) a loss of the sarcolemmal 
dystrophin isoform Dp427 and a drastic reduction in 
dystrophin-associated glycoproteins in contractile cells (5); ii) 
elevated levels of serum creatine kinase indicative of reduced 
muscle fiber integrity (6); iii) a varying degree of muscle 
degeneration ranging from minimal effects in extraocular and 
laryngeal muscle (7) to segmental necrosis in limb muscle 
(8) to severe fiber wasting in diaphragm muscle (9); iv) a high 
susceptibility to osmotic shock (10) or stretch-induced injury 
(11); and v) abnormal calcium-handling (12) including elevated 
cytosolic Ca2+-levels (13). These genetic, biochemical, physi-
ological and cell biological abnormalities have established 
the mdx mouse as a suitable, albeit not precise, genocopy 
and phenocopy of X-linked muscular dystrophy (3). The 
mdx model system has been widely used for testing new 
therapeutic approaches, including myoblast transfer therapy 
(14), gene therapy (15), exon skipping therapy (16) and phar-
macological intervention (17) and is thus a crucial tool for the 
future establishment of new treatment options (18). In contrast 
to considerable phenotypic differences between young mdx 
muscle and human dystrophic specimens, a large number of 
studies have demonstrated that mdx muscle tissue progres-
sively deteriorates with age and more closely resembles the 
human pathology (19).
The age-related mdx pathology includes progressive motor 
weakness (20), loss of myofibers and replacement by extensive 
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connective tissue (21-23), the presence of branched fibers 
that exhibit mechanical weakening of the sarcolemma (24), a 
reduced life span and increased susceptibility to spontaneous 
rhabdomyosarcoma (25), impaired functional and structural 
recovery after injury (26), and a decline in regenerative poten-
tial and alterations in the crucial mTOR signaling pathway, 
which is of central importance for muscle development, muscle 
regeneration, and muscle growth in response to nutrients, 
growth factors and exercise (27). Thus, since senescent mdx 
muscle tissues appear to represent a more suitable dystrophic 
phenotype, it was of interest to determine global changes in the 
protein complement during the natural aging process of mdx 
muscle tissue. This report shows the findings of a comparative 
proteomic analysis of severely affected diaphragm muscle from 
8-week, 12-month and 22-month dystrophic specimens.
Materials and methods
Chemicals and materials. Materials and electrophoresis-grade 
chemicals for the proteomic analysis of muscle proteins were 
purchased from Amersham Biosciences/GE Healthcare (Little 
Chalfont, UK). For protein digestion, sequencing grade-
modified trypsin was obtained from Promega (Madison, WI). 
Chemiluminescence substrate and protease inhibitors were 
from Roche Diagnostics (Mannheim, Germany). Primary 
antibody to collagen VI and secondary peroxidase-conjugated 
antibodies were from Abcam (Cambridge, UK) and Chemicon 
International (Temecula, CA), respectively. All other chemicals 
used were of analytical grade and were purchased from Sigma 
Chemical Co. (Dorset, UK).
Preparation of crude muscle extracts from aged mdx mice. 
The mdx mouse is missing the membrane cytoskeletal protein 
Dp427 due to a point mutation in the dystrophin gene (4) and 
the severely affected mdx diaphragm muscle represents an 
established animal model of Duchenne muscular dystrophy 
(9). Dystrophic diaphragm muscle from 8-week, 12-month and 
22-month mdx mice and normal tissues from age-matched C57 
mice were obtained from the bioresource unit of the University 
of Bonn (26). Mice were kept under standard conditions and 
all procedures were performed in accordance with German 
guidelines on the use of animals for scientific experiments. 
Animals were sacrificed by cervical dislocation and muscle 
tissues were quickly removed and quick-frozen in liquid 
nitrogen. For the proteomic analysis of mdx tissue, specimens 
were shipped to Ireland on dry ice and stored at -80˚C prior to 
usage. In order to obtain diaphragm protein extracts, 4 dystro-
phic muscle specimens from each age group were pulverized 
by grinding tissue pieces in liquid nitrogen using a mortar and 
pestle. Ground muscle powder was solubilized in lysis buffer 
with the ratio of 100 mg wet weight to 1 ml lysis buffer [7 M 
urea, 2 M thiourea, 4% CHAPS, 2% IPG buffer pH 3-10, 2% 
(w/v) DTT]. To prevent excess protein degradation, the lysis 
buffer was supplemented with a freshly prepared protease 
inhibitor cocktail (28). Following gentle rocking for 60 min, 
suspensions were centrifuged at 4˚C for 20 min at 20,000 x g 
and the protein concentration determined (29).
Fluorescence gel electrophoretic analysis. For the separation of 
individual muscle protein species, two-dimensional gel electro-
phoresis was carried out by previously optimized methodology 
using first dimension isoelectric focusing with pH 3-10 strips and 
second dimension slab gel electrophoresis with 500 µg protein/
gel (28-30). Twelve slab gels were run in parallel at 0.5 W/gel 
for 60 min and then 15 W/gel until the blue dye front had disap-
peared from the bottom of the gel. Post-electrophoretic staining 
for the total protein profile was performed with the fluorescent 
dye ruthenium II tris bathophenanthroline disulfonate (RuBPs). 
A stock solution of RuBPs dye was prepared as described previ-
ously by Rabilloud et al (31). Following fixation for 30 min in 
30% ethanol and 10% acetic acid, gels were washed 3 times 
for 30 min in 20% ethanol and then stained for 6 h in 20% 
(v/v) ethanol containing 2 µM of ruthenium chelate. Gels were 
re-equilibrated twice for 10 min in distilled water and destained 
overnight in 40% ethanol and 10% acetic acid prior to imaging 
(32). Fluorescently labelled proteins were visualized using a 
Typhoon Trio variable mode imager (Amersham Biosciences/
GE Healthcare). Gel analysis was performed with Progenesis 
2D analysis software (Nonlinear Dynamics, Newcastle upon 
Tyne, UK) and protein spots with a significant change in abun-
dance were identified by mass spectrometry.
Mass spectrometric identification of muscle-associated 
proteins. Protein identification was performed with 2D protein 
spots from Coomassie-stained pick gels, following counter 
staining of RuBPs-labelled analytical gels. Electrospray ioniza-
tion LC-MS/MS analysis was carried out as previously described 
Figure 1. Two-dimensional gel electrophoretic analysis of aged mdx dia-
phragm muscle. Shown are RuBPs-stained gels of total extracts from 8-week 
(DIA MDX 1-4), 12-month (DIA MDX 5-8) and 22-month (DIA MDX 9-12) 
muscle. Fluorescent images are shown for the pH 3-10 range.
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in detail (29). Previously standardized in-gel tryptic digestion 
protocols were employed for the reproducible generation of 
peptides for mass spectrometric analysis on a Model 6340 Ion 
Trap LC/MS apparatus from Agilent Technologies (Santa Clara, 
CA). Database searches were carried out using Mascot MS/
MS Ion search. Criterion for each search was set at i) species 
Mus musculus, ii) two missed cleavages by trypsin, iii) variable 
modification: oxidation of methioine, iv) fixed modification: 
carboxymethylation of cysteines and v) mass tolerance of 
precursor ions ±2 Da and product ions ±1 Da. Verification of 
key proteomic findings was carried out by comparative immu-
noblot analysis (28).
Results
Gel electrophoretic analysis of aged mdx diaphragm muscle. 
Fluorescence high-resolution 2D gel electrophoresis in 
combination with MS analysis was used to detect potential 
differences in aging-related protein expression patterns in 
severely dystrophic diaphragm muscle from mdx mice. As 
summarized in Fig. 1, gels representing 4 biological repeats 
of 8-week, 12-month and 22-month mdx diaphragm muscle 
were analyzed. The overall 2D spot patterns of differently aged 
dystrophic preparations were relatively comparable; requiring 
therefore detailed denitometric analyses for the determination 
of significant differences in individual muscle proteins. With 
the help of a Typhoon Trio variable imager and Progenesis 2-D 
analysis software, individual muscle proteomes separated on 
12 different gels were compared. Panels DIA MDX 1-4, DIA 
MDX 5-8 and DIA MDX 9-12 represent 8-week, 12-month and 
22-month diaphragm muscle preparations, respectively. The 
detailed proteomic survey of dystrophic diaphragm muscle 
tissue identified distinct changes in a variety of protein species.
Proteomic analysis of protein alterations in aged mdx diaphragm 
muscle. A representative fluorescent 2D master gel of mdx 
Figure 2. Fluorescence gel electrophoretic analysis of mdx diaphragm. Shown 
is a representative RuBPs-labeled master gel of crude tissue extracts from mdx 
diaphragm. Protein spots with an age-related change in expression levels are 
marked by circles and are numbered 1 to 11. See Table I for the mass spectro-
metric identification of individual muscle-associated proteins. The pH-values 
of the first dimension gel system and molecular mass standards of the second 
dimension are indicated on the top and on the left of the panels, respectively.
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diaphragm muscle is shown in Fig. 2. The overall number and 
degree of age-related changes was striking in diaphragm muscle. 
Skeletal muscle proteins that exhibited significant alterations in 
expression levels are marked by circles and are numbered 1 to 11 
in 2D gels of diaphragm muscle. The mass spectrometric identi-
fication of these altered protein species is catalogued in Table I. 
Listed are the names of the identified muscle-associated proteins, 
their international accession number, pI-values, their relative 
molecular masses, the number of matched peptide sequences, 
percentage sequence coverage, Mascot scores, and fold-change 
of individual proteins affected in dystrophin-deficient tissue 
during aging.
Mass spectrometrically identified proteins with an altered abun-
dance in mdx diaphragm muscle. Protein species with a changed 
concentration in mdx diaphragm muscle ranged in molecular 
mass from 20 kDa (αB-crystallin) to 110 kDa (collagen) and 
covered a pI-range from 4.7 (dermatopontin) to 8.6 (myozenin). 
As presented in Fig. 2 and Table I, an increased concentration 
was established for the α-1(VI) chain of collagen (spot 1), the 
extracellular matrix protein dermatopontin (spot 2), the enzyme 
ubiquitin carboxyl-terminal hydrolase (spot 3), the small heat 
shock protein αB-crystallin (spot 4), α-2 actinin (spot 5), ferritin 
heavy chain (spot 6), vimentin (spot 7), the γ chain of fibrinogen 
(spot 8) mimecan (spot 9) and apolipoprotein E (spot 10). Spot 
11 representing myozenin was shown to be decreased in aged 
mdx diaphragm muscle.
Immunoblot analysis of collagen in aged mdx diaphragm 
muscle. In order to independently verify the most drastic 
alteration in aged mdx diaphragm as revealed by proteomics, 
comparative immunoblotting was used. As shown in Fig. 3, 
immunodecoration of gel electrophoretically separated normal 
and mdx diaphragm of varying age showed a general increase 
of collagen in 12-month and 22-month muscle preparations. 
However, aged dystrophic mdx diaphragm muscle exhibited a 
significantly higher increase in collagen as compared to aged 
normal muscle.
Discussion
Animal models that mimic neuromuscular disorders play a 
crucial role in basic and applied myology. Naturally occur-
ring or genetically engineered model systems are widely used 
for studying fundamental aspects of molecular and cellular 
pathogenesis, as well as the evaluation of novel therapeutic 
approaches (33). Ideally, an animal model of a genetic disorder 
should: i) exhibit similar primary abnormalities and secondary 
downstream alterations as seen in the corresponding human 
disease; ii) closely develop most of the multifactorial features 
observed in complex human pathologies; iii) resemble the 
pathogenesis of the human disease in onset, progression and 
severity; iv) show sufficient similarities to human metabolism, 
physiology and immune responses so that these biological 
factors do not have a major differentiating influence on disease 
progression in animal models vs. patients; v) is easy to breed 
and house at a reasonable cost; vi) be suitable for genetic 
manipulations and the facilitation of physiological and surgical 
procedures; and vii) be large enough to yield sufficient amounts 
of tissue specimens for extended biological analyses (34). Since 
an important bioethical objection with respect to the humane 
and responsible use of animal models in biomedical research 
is often associated with the usage of larger animals, small 
rodents are the most frequently used alternatives as genetic 
Figure 3. Immunoblot analysis of collagen in normal vs. mdx diaphragm muscle during aging. Shown are representative immunoblots with expanded views of 
antibody-decorated collagen bands. Lanes 1-3 and lanes 4-6 represent 8-week, 12-month and 22-month normal wild-type (A) vs. dystrophic mdx (B) diaphragm 
muscle, respectively. (C and D) The graphical representation of the immunoblotting of collagen in normal vs. mdx preparations (n=5; ***P<0.001; unpaired t-test), 
respectively.
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model systems. In the case of one the most progressive genetic 
disease of the neuromuscular system, Duchenne muscular 
dystrophy, the naturally occurring dystrophic mdx mouse has 
been employed in a large number of studies (3,35).
In analogy to findings of previous mass spectrometry-based 
proteomic studies of contractile tissues from young or mature 
mdx mice (36) which included hindlimb muscle (37-39), extra-
ocular muscle (30), diaphragm (16,28,40) and heart (29,41), 
we have here carried out a comparative proteomic survey 
of diaphragm muscle from 8-week, 12-month and 22-month 
dystrophic specimens. Dystrophic diaphragm muscle showed 
altered expression levels in 11 proteins during skeletal muscle 
aging. Changes in the diaphragm proteome from aged mdx 
mice suggested elevated levels of fibrosis, an intensified stress 
response and an increase in cytoskeletal elements possibly 
compensating the lack of dystrophin. These proteomic find-
ings agree with the idea of more extensively perturbed protein 
expression levels in dystrophin-deficient diaphragm fibers as 
compared to other mdx muscle systems (36).
The approximately 6-fold increase of collagen and derma-
topontin in senescent mdx diaphragm muscle are important 
proteomic findings and reflect the dystrophic status of this 
muscle type. The dramatic increase of collagen in mdx 
diaphragm was clearly confirmed by immunoblot analysis, veri-
fying the findings from the mass spectrometric investigation 
presented here. Although it is clearly established that collagen 
levels increase in the skeletal muscle extracellular matrix 
during the natural aging process (42), the dystrophic phenotype 
shows an exacerbated age-related accumulation of collagen 
α-1(VI) chain. Collagen is the main protein component of 
connective tissue and is especially enriched in the endomysium 
of skeletal muscles. Increased collagen protein levels agree 
with previously reported greater amounts of collagen mRNA in 
the mdx diaphragm (43) and support the idea of severe fibrosis 
in the mdx diaphragm (44,45). The non-collagenous extracel-
lular matrix protein dermatopontin is involved in cell-matrix 
interactions and matrix assembly (46) and also named tyrosine-
rich acidic matrix protein (TRAMP) (47). TRAMP appears to 
regulate interactions of TGF-β, decorin and fibronectin (48). 
Its greater abundance in mdx diaphragm is probably due to 
increased demands for collagen matrix organization within 
dystrophic muscle tissues. Increased levels of fibrinogen in 
aged mdx diaphragm, as shown here by proteomics, agree with 
a previous study by Vidal et al (49). Fibrinogen seems to play a 
key role in fibrosis via a TGF-β/alternative macrophage activa-
tion pathway in dystrophinopathy (49).
The increase of αB-crystallin and vimentin suggests an 
increased cellular stress response and an upregulation of 
cytoskeletal elements in dystrophic muscle, respectively, which 
agrees with previous proteomic studies (28). In the future, it 
will be interesting to define the potential pathobiochemical role 
of newly identified biomarkers of muscular dystrophy in aged 
mdx diaphragm muscle, including the deubiqutinating enzyme 
ubiquitin carboxyl-terminal hydrolase, the microfilament 
protein actinin and its binding protein myozenin, the intracel-
lular iron storage component ferritin, the connective tissue 
protein mimecan, and the triglyceride transporter apolipopro-
tein E. Overall, the proteomic results presented here suggest 
that the aged mdx diaphragm, which exhibits severe respiratory 
impairment following fibrosis (50), is a highly suitable model 
system for studying the molecular pathogenesis of Duchenne 
muscular dystrophy. Collagen and dermatopontin should be 
considered as suitable biomarker candidates for evaluating the 
degree of fibrosis and tissue scaring in dystrophinopathy.
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